Recruiting
Phase 1
Phase 2

KITE-363 & KITE-753

Sponsor:

Kite, A Gilead Company

Code:

NCT04989803

Conditions

Relapsed and/or Refractory B-cell Lymphoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Cyclophosphamide

Fludarabine

KITE-363

KITE-753

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-02. This information was provided to ClinicalTrials.gov by Kite, A Gilead Company on 2026-08-28.